Scripps Research teams are looking for anti-viral drugs that could be given to people already exposed to the novel coronavirus causing the COVID-19 pandemic. One priority is to test already approved drugs, or drugs with significant safety data in humans available, which could be made available to treat coronavirus patients on a much quicker timescale than new therapies.
To do this, Calibr—the drug development division of Scripps Research—is leveraging a unique resource, the ReFRAME drug repurposing collection. With support from the Bill & Melinda Gates Foundation, Calibr compiled ReFRAME, the world’s leading collection of known drugs, comprising over 14,000 compounds that have been approved by the FDA for other diseases or have been extensively tested for human safety.
Visit Technology Networks' hubpage to stay updated with all the latest news on the current coronavirus outbreak.
Repurposing Existing Drugs for Coronavirus: Scripps Research COVID-19 Updates
Video Mar 24, 2020 | Taken from Scripps Research, YouTube
Advertisement
Recommended Videos
Video
The novel coronavirus sweeping the globe packs 27 proteins, each adopting a unique, often incredibly complex 3D structure. Each protein is part of the molecular toolkit that the virus uses to infect, replicate, and spread. Understanding the proteins' structures provides a blueprint for drug designs.
WATCH NOWLike what you just watched? You can find similar content on the communities below.
Biopharma Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Advertisement
